Compare Stocks: DMAC, SEPN, ZBIO, and NUVB

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DMAC DiaMedica Therapeutics	$7.71 -1.4%	$7.12	$5.24 ▼ $10.42	$415.53M	0.92	198,929 shs	103,261 shs
NUVB Nuvation Bio	$4.69 -0.6%	$6.13	$3.36 ▼ $9.75	$1.65B	1.61	5.51 million shs	1.60 million shs
SEPN Septerna	$36.27 -0.4%	$39.44	$17.55 ▼ $51.10	$1.69B	2.29	364,760 shs	68,422 shs
ZBIO Zenas BioPharma	$24.75 -1.6%	$30.59	$13.50 ▼ $44.60	$1.62B	-0.9	810,557 shs	88,754 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DMAC DiaMedica Therapeutics	-4.63%	-3.81%	+20.87%	+2.36%	+10.76%
NUVB Nuvation Bio	-3.51%	-2.86%	-22.60%	-19.78%	+28.22%
SEPN Septerna	-3.04%	+2.10%	-5.43%	+6.90%	+51.18%
ZBIO Zenas BioPharma	-4.70%	-6.61%	-19.15%	-14.45%	-5.20%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DMAC DiaMedica Therapeutics	$7.71 -1.4%	$7.12	$5.24 ▼ $10.42	$415.53M	0.92	198,929 shs	103,261 shs
NUVB Nuvation Bio	$4.69 -0.6%	$6.13	$3.36 ▼ $9.75	$1.65B	1.61	5.51 million shs	1.60 million shs
SEPN Septerna	$36.27 -0.4%	$39.44	$17.55 ▼ $51.10	$1.69B	2.29	364,760 shs	68,422 shs
ZBIO Zenas BioPharma	$24.75 -1.6%	$30.59	$13.50 ▼ $44.60	$1.62B	-0.9	810,557 shs	88,754 shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DMAC DiaMedica Therapeutics	-4.63%	-3.81%	+20.87%	+2.36%	+10.76%
NUVB Nuvation Bio	-3.51%	-2.86%	-22.60%	-19.78%	+28.22%
SEPN Septerna	-3.04%	+2.10%	-5.43%	+6.90%	+51.18%
ZBIO Zenas BioPharma	-4.70%	-6.61%	-19.15%	-14.45%	-5.20%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DMAC DiaMedica Therapeutics	2.60	Moderate Buy	$12.00	55.84% Upside
NUVB Nuvation Bio	2.67	Moderate Buy	$13.22	180.43% Upside
SEPN Septerna	2.82	Moderate Buy	$52.44	45.46% Upside
ZBIO Zenas BioPharma	2.56	Moderate Buy	$46.71	88.06% Upside

Current Analyst Ratings Breakdown

Latest DMAC, SEPN, ZBIO, and NUVB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/13/2026	ZBIO Zenas BioPharma	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$44.00
10/6/2026	ZBIO Zenas BioPharma	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
9/30/2026	ZBIO Zenas BioPharma	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$41.00 ➝ $48.00
9/30/2026	ZBIO Zenas BioPharma	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$55.00
9/30/2026	NUVB Nuvation Bio	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Market Outperform ➝ Buy	$12.00
9/30/2026	ZBIO Zenas BioPharma	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform	$45.00
9/30/2026	ZBIO Zenas BioPharma	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$44.00
9/16/2026	NUVB Nuvation Bio	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Market Outperform
9/16/2026	NUVB Nuvation Bio	Citizens Jmp Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Market Outperform	$10.00
9/16/2026	NUVB Nuvation Bio	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform	$11.00
8/21/2026	NUVB Nuvation Bio	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Overweight

(Data available from 10/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DMAC DiaMedica Therapeutics	N/A	N/A	N/A	N/A	$1.08 per share	N/A
NUVB Nuvation Bio	$62.90M	26.32	N/A	N/A	$0.88 per share	5.36
SEPN Septerna	$45.95M	36.63	N/A	N/A	$8.53 per share	4.23
ZBIO Zenas BioPharma	$10M	161.91	N/A	N/A	$4.51 per share	5.51

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DMAC DiaMedica Therapeutics	-$32.77M	-$0.72	N/A	N/A	N/A	N/A	-77.76%	-69.43%	11/11/2026 (Estimated)
NUVB Nuvation Bio	-$204.63M	-$0.44	N/A	N/A	N/A	-88.18%	-46.59%	-22.01%	11/2/2026 (Estimated)
SEPN Septerna	-$48.88M	-$0.54	N/A	N/A	N/A	-24.51%	-9.57%	-6.28%	11/9/2026 (Estimated)
ZBIO Zenas BioPharma	-$377.74M	-$8.99	N/A	N/A	N/A	N/A	-122.45%	-58.04%	11/12/2026 (Estimated)

Latest DMAC, SEPN, ZBIO, and NUVB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2026	Q3 2026	DMAC DiaMedica Therapeutics	-$0.20	N/A	N/A	N/A	$13.50 million	N/A
11/9/2026	Q3 2026	SEPN Septerna	-$0.4150	N/A	N/A	N/A	$20.78 million	N/A
11/2/2026	Q3 2026	NUVB Nuvation Bio	-$0.1221	N/A	N/A	N/A	$34.81 million	N/A
8/13/2026	Q2 2026	ZBIO Zenas BioPharma	-$1.12	-$1.77	-$0.65	-$1.77	$15.00 million	$1.00 million
8/10/2026	Q2 2026	DMAC DiaMedica Therapeutics	-$0.2009	-$0.19	+$0.0109	-$0.19	$13.50 million	N/A
8/10/2026	Q2 2026	SEPN Septerna	-$0.4260	-$0.29	+$0.1360	-$0.29	$19.22 million	$26.75 million
8/6/2026	Q2 2026	NUVB Nuvation Bio	-$0.1417	-$0.15	-$0.0083	-$0.18	$27.03 million	$31.69 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DMAC DiaMedica Therapeutics	N/A	N/A	N/A	N/A	N/A
NUVB Nuvation Bio	N/A	N/A	N/A	N/A	N/A
SEPN Septerna	N/A	N/A	N/A	N/A	N/A
ZBIO Zenas BioPharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DMAC DiaMedica Therapeutics	N/A	6.72	6.72
NUVB Nuvation Bio	0.96	8.37	8.14
SEPN Septerna	N/A	4.99	4.99
ZBIO Zenas BioPharma	1.57	9.93	9.93

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DMAC DiaMedica Therapeutics	10.12%
NUVB Nuvation Bio	61.67%
SEPN Septerna	N/A
ZBIO Zenas BioPharma	N/A

Insider Ownership

Company	Insider Ownership
DMAC DiaMedica Therapeutics	5.00%
NUVB Nuvation Bio	30.11%
SEPN Septerna	5.80%
ZBIO Zenas BioPharma	22.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DMAC DiaMedica Therapeutics	35	53.93 million	51.23 million	Optionable
NUVB Nuvation Bio	305	351.12 million	245.40 million	Optionable
SEPN Septerna	130	46.68 million	43.97 million	N/A
ZBIO Zenas BioPharma	167	65.18 million	50.84 million	N/A

DMAC, SEPN, ZBIO, and NUVB Headlines

Recent News About These Companies

Zenas BioPharma Highlights New Phase 3 Obexelimab Data

1 hour ago | theglobeandmail.com

Zenas BioPharma's (ZBIO) "Buy" Rating Reaffirmed at HC Wainwright

October 13 at 8:05 AM | marketbeat.com

Zenas BioPharma (ZBIO) Is Down 5.1% After New Phase 3 Obexelimab IgG4-RD Data Release

October 13 at 7:29 AM | uk.finance.yahoo.com

Zenas BioPharma Announces the Presentation of New Obexelimab Data in IgG4-Related Disease at the 6th International Symposium on IgG4-Related Disease

October 12 at 7:45 AM | markets.businessinsider.com

Head-To-Head Review: MacroGenics (NASDAQ:MGNX) vs. Zenas BioPharma (NASDAQ:ZBIO)

October 12 at 5:14 AM | americanbankingnews.com

Zenas BioPharma, Inc. (ZBIO) - What Are Researchers Saying About This Stock?

October 12 at 2:15 AM | americanbankingnews.com

Zenas BioPharma, Inc. (ZBIO) - What Are Analysts Thinking About This Stock?

October 12 at 2:13 AM | marketbeat.com

Zenas Biopharma Inc (ZBIO)

October 10, 2026 | investing.com

Zenas BioPharma Announces Upcoming Presentations of Orelabrutinib Data in Relapsing Remitting Multiple Sclerosis, Clinical Trial Designs in Progressive Multiple Sclerosis

October 8, 2026 | marketscreener.comM

Zenas BioPharma Announces Upcoming Presentations of Orelabrutinib Data in Relapsing Remitting Multiple Sclerosis, Clinical Trial Designs in Progressive Multiple Sclerosis

October 8, 2026 | marketscreener.comM

Zenas BioPharma (NASDAQ:ZBIO) Shares Down 6.2% - Time to Sell?

October 8, 2026 | marketbeat.com

Zenas BioPharma Announces Upcoming Presentations of Orelabrutinib Data in Relapsing Remitting Multiple Sclerosis, Clinical Trial Designs in Progressive Multiple Sclerosis and ...

October 7, 2026 | markets.businessinsider.com

Zenas BioPharma (NASDAQ:ZBIO) Stock Jumps 3.3% - Should You Buy?

October 7, 2026 | marketbeat.com

Zenas BioPharma Announces Upcoming Presentations of Orelabrutinib Data in Relapsing Remitting Multiple Sclerosis, Clinical Trial Designs in Progressive Multiple Sclerosis and Other Multiple Sclerosis Portfolio Data at MSToronto2026

October 7, 2026 | globenewswire.com

Zenas BioPharma to Host Virtual R&D Event on October 27, 2026

October 6, 2026 | quiverquant.comQ

Zenas BioPharma to Host Virtual R&D Event

October 6, 2026 | globenewswire.com

Zenas BioPharma: Obexelimab Is Being Graded On The Wrong Curve

October 5, 2026 | seekingalpha.com

Zenas BioPharma (NASDAQ:ZBIO) Stock Price Up 7.1% - Still a Buy?

October 1, 2026 | marketbeat.com

Zenas BioPharma's Obexelimab Faces Larger IgG4-RD Opportunity, Wedbush Says

September 30, 2026 | marketscreener.comM

Wedbush Reaffirms Outperform Rating for Zenas BioPharma (NASDAQ:ZBIO)

September 30, 2026 | marketbeat.com

Zenas BioPharma (NASDAQ:ZBIO) Earns Buy Rating from HC Wainwright

September 30, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DMAC, SEPN, ZBIO, and NUVB Company Descriptions

DiaMedica Therapeutics NASDAQ:DMAC

$7.71 -0.11 (-1.42%)

As of 12:43 PM Eastern

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Nuvation Bio NYSE:NUVB

$4.69 -0.03 (-0.55%)

As of 12:44 PM Eastern

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.

Septerna NASDAQ:SEPN

$36.27 -0.15 (-0.42%)

As of 12:43 PM Eastern

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body. Due to their significant role in human diseases, GPCRs have been the most productive target class in drug discovery history, accounting for approximately one-third of all U.S. Food and Drug Administration (FDA) approved drugs, representing approximately 500 products with combined global revenue of approximately $125 billion in 2023. Despite the pharmacological and commercial success of GPCR-targeted agents, about 75% of potential GPCR therapeutic targets remain undrugged and, for certain validated GPCRs, novel binding pockets may exist that could offer enhanced therapeutic benefits. Each step in GPCR activation involves subtle conformational changes that have been historically challenging to reproduce outside of a cell. The inability to isolate GPCR proteins in their native functional form outside of a cellular context has prevented scientists from leveraging some of the state-of-the-art technologies that have revolutionized drug discovery in other major target classes over the past decade. This complex challenge has limited GPCR drug discovery, particularly the development of novel oral small molecules, such as agonists (which activate GPCR signaling) for peptide GPCRs and allosteric modulators (which either increase or decrease the degree of GPCR activation by endogenous ligands). Our proprietary Native Complex Platform™ replicates the natural structure, function, and dynamics of GPCRs outside of cells at an industrial scale for, as we believe it, the first time. Our foundational technologies enable us to isolate, purify, and reconstitute full-length, properly folded GPCR proteins within ternary complexes with ligands and transducer proteins in a lipid bilayer that mimics the cell membrane. We then apply state-of-the-art discovery tools and technologies to these defined and tunable protein complexes to structurally design, screen for, and optimize potential product candidates. Leveraging our platform, we conduct GPCR oral small molecule drug discovery using an industrialized and iterative structure-based drug design approach for a diverse collection of GPCR targets. Our Native Complex PlatformTM is designed to enable us to target specific GPCRs, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists, antagonists (which inhibit GPCR signaling), and allosteric modulators, to affect GPCR signaling in different ways to achieve desired therapeutic effects. We are advancing a deep portfolio of oral small molecule GPCR-targeted programs with novel mechanistic approaches to treat diseases across multiple therapeutic areas for patients with significant unmet needs. Our wholly-owned pipeline, is focused initially on three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. We intend to evaluate opportunities in other major therapeutic areas, such as neurology, women's health, cardiovascular, and respiratory disease. --- Leveraging our team, scientific and technical advisors, and our proprietary Native Complex Platform™, we aim to be a leader in the development of oral GPCR-targeted medicines for patients with significant unmet needs. We were incorporated under the laws of the State of Delaware in December 2019 under the name GPCR NewCo, Inc. and changed our name to Septerna, Inc. in June 2021. Our principal executive offices are located at 250 East Grand Avenue, South San Francisco, California.

Zenas BioPharma NASDAQ:ZBIO

$24.75 -0.41 (-1.65%)

As of 12:43 PM Eastern

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DMAC, SEPN, ZBIO, and NUVB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DMAC, SEPN, ZBIO, and NUVB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DMAC, SEPN, ZBIO, and NUVB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

DMAC, SEPN, ZBIO, and NUVB Company Descriptions

DiaMedica Therapeutics NASDAQ:DMAC

Nuvation Bio NYSE:NUVB

Septerna NASDAQ:SEPN

Zenas BioPharma NASDAQ:ZBIO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DMAC, SEPN, ZBIO, and NUVB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DMAC, SEPN, ZBIO, and NUVB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DMAC, SEPN, ZBIO, and NUVB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

DMAC, SEPN, ZBIO, and NUVB Company Descriptions

DiaMedica Therapeutics NASDAQ:DMAC

Nuvation Bio NYSE:NUVB

Septerna NASDAQ:SEPN

Zenas BioPharma NASDAQ:ZBIO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools